Company Overview
Snapshot
Founded in July 2015 by Doron Chema and Yisrael Gross, L7 Defense operated with 11–50 employees. The company raised a total of $4.95 million across three funding rounds from three investors. In January 2021, L7 Defense secured Series A funding from TRUMPF Venture and Quick Heal Technologies.
Business overview
L7 Defense developed advanced API protection solutions to safeguard organizations against API-borne attacks, which pose significant risks to infrastructure, applications, and data sharing. The company's core technology, Ammune, utilized disruptive, AI-based technology, specifically unsupervised-learning AI, for applicative protection at the API resolution. L7 Defense operated within the Cyber Security sector, serving enterprises and financial institutions globally.
Strategic signal
L7 Defense ceased operations in February 2024, indicating a significant shift in its market presence and strategic direction. This cessation of activity signals to investors and innovation teams that the company is no longer an active player in the API security market, prompting a re-evaluation of the competitive landscape and potential alternative solutions.
Company Intelligence Q&A
- What is L7 Defense's primary focus?
- L7 Defense specializes in advanced API protection solutions, safeguarding organizations' infrastructure, applications, customers, employees, and partners from API-borne attacks.
- When was L7 Defense founded and by whom?
- L7 Defense was founded in July 2015 by Doron Chema and Yisrael Gross.
- What was a key recognition for L7 Defense's technology?
- In October 2020, L7 Defense was awarded the 2020 Global Product Leadership Award by Frost & Sullivan for its fully autonomous AI-based API security solution, Ammune.
- Which investors participated in L7 Defense's Series A funding round?
- In January 2021, L7 Defense raised Series A funding from TRUMPF Venture and Quick Heal Technologies.
- What is the current operational status of L7 Defense?
- L7 Defense ceased to operate in February 2024.